Genvec Inc (GNVC1)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Douglas J. Swirsky
Employees:
15
910 CLOPPER ROAD, SUITE 220N, GAITHERSBURG, MD 20878
2406320740

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

GenVec, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the United States.

Data derived from most recent annual or quarterly report
Market Cap 16.328 Million Shares Outstanding2.27 Million Avg 30-day Volume 9.743 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.61
Price to Revenue41.129 Debt to Equity0.0 EBITDA-8.576 Million
Price to Book Value23.6333 Operating Margin-2585.9701 Enterprise Value9.493 Million
Current Ratio2.093 EPS Growth0.093 Quick Ratio1.99
1 Yr BETA 0.6386 52-week High/Low 0.0 / Profit Margin-2447.7612
Operating Cash Flow Growth-23.7381 Altman Z-Score-87.4141 Free Cash Flow to Firm -3.243 Million
View SEC Filings from GNVC1 instead.

View recent insider trading info

Funds Holding GNVC1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding GNVC1

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2017-06-16:
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2017-06-15:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2017-05-17:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2017-01-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-12-16:
    Item 8.01: Other Events
  • 8-K: filed on 2016-12-01:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-11-16:
    Item 8.01: Other Events
  • 8-K: filed on 2016-11-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-10-24:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2016-09-01:
    Item 7.01: Regulation FD Disclosure
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    KELLEY WILLAM N

    • Director
    No longer subject to file 2017-06-16 0

    HOCKMEYER WAYNE T

    • Director
    No longer subject to file 2017-06-16 0

    BUTMAN BRYAN T SENIOR VICE PRESIDENT

    • Officer
    No longer subject to file 2017-06-16 0

    RICHMAN MICHAEL

    • Director
    No longer subject to file 2017-06-16 0

    SWIRSKY DOUGLAS J PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2017-06-16 0

    SCHNEEBAUM MARC R

    • Director
    No longer subject to file 2017-06-16 0

    LOREN STEFAN

    • Director
    No longer subject to file 2017-06-16 0

    BROUGH DOUGLAS E CHIEF SCIENTIFIC OFFICER

    • Officer
    No longer subject to file 2017-06-16 0

    MALLETTE QUINTEROL J

    • Director
    No longer subject to file 2017-06-16 0

    LAMBERT JAMES VINCENT VP, ACCOUNTING & FINANCE

    • Officer
    No longer subject to file 2017-06-16 0

    MMCAP INTERNATIONAL INC. SPC

    • 10% Owner
    257,272 2017-03-03 0

    ECOR1 CAPITAL, LLC

    ECOR1 CAPITAL FUND, L.P.

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    NODELMAN OLEG

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    5,936,559 2014-05-22 0

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    • SEE EXPLANATION OF RESPONSES
    736,457 2014-03-26 0

    ECOR1 CAPITAL, LLC

    ECOR1 CAPITAL FUND, L.P.

    NODELMAN OLEG

    • 10% Owner
    1,840,000 2013-11-25 0

    HOROVITZ ZOLA P

    • Director
    80,757 2013-09-03 0

    COLLINS CYNTHIA PRESIDENT & CEO

    • Officer
    • Director
    0 2013-01-23 0

    MAHMOUD ADEL

    • Director
    0 2012-07-11 0

    CONNOR EDWARD M

    • Director
    0 2012-07-11 0

    ROONEY KEVIN M

    • Director
    0 2012-07-11 0

    FISCHER PAUL H PRESIDENT & CEO

    • Officer
    • Director
    0 2012-01-18 0

    TUCKER MICHAEL C VP, LEGAL AFFAIRS AND STRATEGY

    • Officer
    0 2012-01-18 0

    RUCH JOSHUA

    • Director
    0 2010-06-16 0

    THORNTON MARK OWENS SENIOR VICE PRESIDENT

    • Officer
    0 2010-01-20 0

    KING CHARLES RICHTER SENIOR VICE PRESIDENT

    • Officer
    0 2009-01-22 0

    WERNER HAROLD R

    • Director
    15,000 2007-06-13 0

    PATEL NITA U VICE PRESIDENT

    • Officer
    30,000 2007-01-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments